New clinical trial find that immune drug ‘nivolumab’ improve immune system to fight against most common form of lung cancer. Nivolumab increases the survival rate among those patients who suffering from squamous non-small cell lung cancer. Research said patients taking nivolumab have 27% lesser risk of death with comparison to patients taking docetaxel - a